VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

ACTRIMS 2022 | Study of real-world evidence in patients with PMS and RMS treated with ocrelizumab

Ocrelizumab is an anti-CD20 antibody used to treat relapsing (RMS) and progressive multiple sclerosis (PMS). Virginia Meca-Lallana, MD, La Princesa University Hospital, Madrid, Spain, summarizes the findings of an observational study of real-world evidence in patients with PMS and RMS, treated with ocrelizumab. A total of 59 patients with PMS and 82 patients with RMS were studied, with the majority of RMS patients being women and younger than the PMS cohort. The RMS patients, before starting ocrelizumab, presented with higher baseline MRI activity than the PMS group. The overall reduction in relapse rate after 2 years of treatment was 85%, with no significant changes to Expanded Disability Status Scale (EDSS) and no MRI activity. In patients with PMS, EDSS was stable with a small increase after 36 months. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.